Jabez Biosciences, Inc., a clinical-stage biopharmaceutical company dedicated to ushering in the future of cancer therapy with their seamless, scalable and synergistic approach, today announced that ...

In addition, rYojbaba has granted the underwriters a 45-day option to purchase up to an additional 187,500 Common Shares at the public offering price per share, less the underwriting discount, to ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) approved Tonmya™ (cyclobenzaprine HCl ...

Streamex is a RWA and gold tokenization company building Institutional grade infrastructure to bring the gold market on chain, enabled by a gold denominated treasury and an institutional grade ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy ® (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) ...

TAMPA, Fla., Aug. 15, 2025 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV), a leader in senior care through the Program of All-inclusive Care for the Elderly (“PACE”), is proud ...

"Bioxytran is poised to lead the oxygen therapeutics revolution," said Avraham Mayevsky, Member of Bioxytran’s Medical Advisory Board. "The principles in this book, tracing tissue oxygenation, could ...

Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced that it will present at the ...

OTTAWA, Ontario, Aug. 15, 2025 (GLOBE NEWSWIRE) -- The Canadian Red Cross has launched the 2025 Newfoundland & Labrador Wildfires Appeal to help people and communities impacted by fires in the ...

The Inducement Grants were granted pursuant to Aligos’ 2024 Inducement Plan (the “Plan”) as an inducement material to these individuals entering employment in accordance with Nasdaq Listing Rule 5635 ...

OCALA, Fla., Aug. 15, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported its financial results for the second quarter 2025.